{"filing":{"accession_number":"0001437749-26-017799","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"eton20260518_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/eton20260518_8k.htm"},"events":[{"id":10168,"run_id":8914,"accession_number":"0001437749-26-017799","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.89,"summary":"Eton entered into and completed a material supply and distribution agreement with Knight Therapeutics on May 18, 2026, acquiring exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine). The transaction includes $4.25 million in fixed fees through March 31, 2032, up to $4.0 million in milestone payments, and royalties of 50–55% of net sales, directly expanding Eton's product portfolio with an orphan drug that generated $8.1 million in U.S. sales in 2025.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":[{"id":280,"accession_number":"0001437749-26-017799","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Eton entered into a material definitive supply and distribution agreement on May 18, 2026 granting exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine) from Knight Therapeutics. The agreement involves $4.25 million in fixed fees over the initial term (through March 31, 2032), up to $4.0 million in milestone payments tied to cumulative net sales, and ongoing royalties of 50–55% of net sales. This constitutes a material acquisition of commercial rights to an orphan drug product with existing 2025 U.S. sales of $8.1 million, directly expanding Eton's product portfolio and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:05.569161+00:00","company_name":"","ticker":null,"filing_date":""},{"id":281,"accession_number":"0001437749-26-017799","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of a supply and distribution agreement for U.S. commercialization rights to IMPAVIDO® (miltefosine), a pharmaceutical product. This represents acquisition of material commercial rights that would affect the company's revenue-generating capabilities and strategic positioning. The reference to Item 1.01 (entry into agreement) and Item 2.01 (completion) indicates a material transaction in the company's business operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:05.569161+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":280,"accession_number":"0001437749-26-017799","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Eton entered into a material definitive supply and distribution agreement on May 18, 2026 granting exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine) from Knight Therapeutics. The agreement involves $4.25 million in fixed fees over the initial term (through March 31, 2032), up to $4.0 million in milestone payments tied to cumulative net sales, and ongoing royalties of 50–55% of net sales. This constitutes a material acquisition of commercial rights to an orphan drug product with existing 2025 U.S. sales of $8.1 million, directly expanding Eton's product portfolio and revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:05.569161+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-05-19"},{"id":281,"accession_number":"0001437749-26-017799","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of a supply and distribution agreement for U.S. commercialization rights to IMPAVIDO® (miltefosine), a pharmaceutical product. This represents acquisition of material commercial rights that would affect the company's revenue-generating capabilities and strategic positioning. The reference to Item 1.01 (entry into agreement) and Item 2.01 (completion) indicates a material transaction in the company's business operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:05.569161+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-05-19"}]}